Serum S100B protein: a useful marker in obstructive sleep apnea syndrome

Duru, Serap; Firat, İbrahim; Colak, Nujen; Giniş, Zeynep; Delibaşı, Tuncay; Ardıç, Sadık

doi:10.5114/ninp.2012.31355

Cited by 10 publications

(15 citation statements)

References 20 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The circulating levels of VEGF are frequently increased in OSA patients and play a role in the regulation of tissue oxygen delivery [22,28]. The levels of IL-8 have been reported to be higher in OSA patients than those in healthy controls [16,29], while the S100B levels are increased in OSA patients but do not correlate with the severity of the disease [24,30]. We only observed increased levels of VCAM-1 and moderate increased levels of VEGF, which may be due to the differences between the populations since our cohort included patients with cutaneous melanoma and OSA; the cutaneous melanoma effect, that is independently related with the increase of VEGF [31,32], together with IL-8 [28,32], ICAM-1 [18,33], S100B [7,34,35] and MIA [7,35,36], could mask the OSA effect on these proteins, which may explain why we did not observe the previously reported differences in these biomarkers in the patients with OSA.…”

Section: Discussionmentioning

confidence: 99%

“…Systemic inflammation due to hypoxia-reoxygenation cycles in OSA may activate diverse physiopathological pathways that enhance tumour progression [14,15]. Both diseases are associated with elevated circulating levels of adhesion molecules, such as intercellular adhesion molecule (ICAM)-1 [16][17][18] and vascular cell adhesion molecule (VCAM)-1 [17,19,20]; inflammation cytokines, such as vascular endothelial growth factor (VEGF) [21,22] and interleukin (IL)-8 [7,16,23]; and biomarkers of the prognosis and severity of melanoma, such as S100 calcium binding protein B (S100B) [7,24] and melanoma inhibitory activity (MIA) [7].…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea

et al. 2018

View full text Add to dashboard Cite

The goal of this study was to assess the relationship between the severity of obstructive sleep apnoea (OSA) and the levels of carcinogenesis- and tumour growth-related biomarkers in patients with cutaneous melanoma.This multicentre observational study included patients who were newly diagnosed with melanoma. The patients were classified as non-OSA (apnoea-hypopnoea index (AHI) 0-5 events·h), mild OSA (AHI 5-15 events·h) and moderate-severe OSA (AHI >15 events·h). ELISAs were performed to analyse the serum levels of hypoxia- and tumour adhesion-related biomarkers (vascular endothelial growth factor (VEGF), interleukin (IL)-8, intracellular adhesion molecule (ICAM) and vascular cell adhesion molecule (VCAM)-1) and markers of tumour aggressiveness (S100 calcium-binding protein B (S100B) and melanoma inhibitory activity (MIA)). A logistic model adjusted for age, sex and body mass index was fitted to each biomarker, and the AHI served as the dependent variable.360 patients were included (52.2% male, median (interquartile range) age 55.5 (43.8-68.0) years and AHI 8.55 (2.8-19.5) events·h). The levels of VEGF, IL-8, ICAM-1, S100B and MIA were not related to the severity of OSA. The levels of VCAM-1 were higher in patients with OSA than those without OSA (mild OSA: odds ratio (OR) 2.07, p=0.021; moderate-severe OSA: OR 2.35, p=0.013).In patients with cutaneous melanoma, OSA was associated with elevated circulating levels of VCAM-1 that could indicate the contribution of OSA in tumorigenesis integrin-based adhesion.

show abstract

Section: Discussionmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea

et al. 2018

View full text Add to dashboard Cite

show abstract

“…The studies were published from 2002 to 2017. Two studies were reported in Germany [10,21], two in Brazil [15,17], one in the Czech Republic [16], three in Turkey [18][19][20], and one in Egypt [22]. Three were crosssectional studies [10,16,17], and six were casecontrol studies [15,[18][19][20][21][22].…”

Section: Resultsmentioning

confidence: 99%

“…In addition, the S100B level was not significantly correlated with OSAS severity. Several studies [15,[19][20][21][22] reported higher serum S100B levels in OSAS patients than in the controls, indicating a significant difference in four studies [15,19,21,22]. Two studies [15,18] showed that the serum NSE level was significantly in OSAS patients higher than in the controls.…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

The effect of obstructive sleep apnea syndrome on serum S100B and NSE levels: a systematic review and meta-analysis of observational studies

et al. 2020

View full text Add to dashboard Cite

Background: Obstructive sleep apnea syndrome (OSAS) is a common disorder that is accompanied by structural brain changes. This meta-analysis aimed to evaluate the effect of OSAS on the serum levels of astrocytic protein (S100B) and neuron-specific enolase (NSE) in observational studies. Methods: A comprehensive search was performed in the PubMed/Medline, Web of Science, Scopus, ScienceDirect, and Cochrane Library databases to assess the serum level of S100B and/or NSE in patients with OSAS and/or controls. The quality of the study was evaluated by the Newcastle-Ottawa Scale (NOS). A random-effects model was performed using RevMan 5.3 with the mean difference (MD) and 95% confidence intervals (CIs). Results: Out of 63 studies found in the mentioned databases and one identified by a manual search, nine studies were included and analyzed in this meta-analysis (three cross-sectional and six case-control studies). The analysis showed that the S100B [MD = 53.58 pg/ml, 95%CI: 1.81, 105.35; P = 0.04] and NSE levels [MD = 3.78 ng/ml, 95%CI: 2.07, 5.48; P < 0.0001] were significantly higher in patients than the controls. However, there were no significant differences between the S100B [MD =-28.00 pg/ml, 95%CI: − 79.48, 23.47; P = 0.29] and NSE levels [MD = 0.49 ng/ml, 95%CI: − 0.82, 1.80; P = 0.46]. Conclusions: This meta-analysis found elevated serum S100B and NSE levels in OSAS patients compared to the controls, which suggests that these markers may be used as peripheral indicators of brain damage in OSAS.

show abstract

Obstructive Sleep Apnoea and Hypertension: the Role of the Central Nervous System

Henderson

Macefield

2016

Curr Hypertens Rep

View full text Add to dashboard Cite

Recent human brain imaging investigations and, in particular, combined microneurography recording of resting sympathetic activity with high-resolution functional magnetic resonance imaging have provided some important insights into changes in brain function and anatomy associated with resting sympathetic activity. Functional and anatomical changes occur in OSA, including in regions of the brainstem circuitry known to be responsible for setting resting sympathetic activity. Furthermore, these changes are reversed following continuous positive airway treatment in concert with reductions in resting sympathetic drive. These resent findings suggest that the central changes may contribute significantly to the hypertension associated with OSA.

show abstract

Serum S100B protein: a useful marker in obstructive sleep apnea syndrome

Abstract: Serum S100B protein level is increased in patients with OSAS and may be a useful biochemical marker in those patients.

Cited by 10 publications

References 20 publications

Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea

Biomarkers of carcinogenesis and tumour growth in patients with cutaneous melanoma and obstructive sleep apnoea

The effect of obstructive sleep apnea syndrome on serum S100B and NSE levels: a systematic review and meta-analysis of observational studies

Obstructive Sleep Apnoea and Hypertension: the Role of the Central Nervous System

Contact Info

Product

Resources

About